Kuraray : to End the Manufacture and Sale of Bone-graft Substitutes
March 24, 2024 at 10:19 pm EDT
Share
Kuraray Co., Ltd. Kuraray Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Hitoshi Kawahara; hereinafter "Kuraray") hereby announces its decision to end the manufacture and sale of bone-graft substitutes. Due to changes in the market environment, we have judged that it will be extremely difficult to secure sufficient profit to sustain the business and maintain stable production going forward.
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.
Attachments
Original Link
Permalink
Disclaimer
Kuraray Co. Ltd. published this content on
25 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
25 March 2024 02:18:06 UTC.
Kuraray Co., Ltd. is the world's leader in the manufacturing and marketing of chemical products, resins and synthetic fibers. Net sales break down by family of products as follows:
- chemical and resin (45.6%): functional resins and films, elastometers, thermoplastics, adhesives, fine chemistry products, etc. primarily for cosmetic products, televisions and mobile phones screens, foot packaging and paper manufacturing;
- fibers and textile products (29.8%): synthetic fibers and man-made leather, polyester, nonwoven textile products, resins, etc. sold under the brands Kuralon, Clarino Vectran and Kuraflex;
- functional materials (18.8%): methacrylic resin, medical chemicals, carbon materials, etc.;
- other (5.8%): primarily dental treatment and water purifying products.
At the end of 2019, the group had 52 production worldwide.
Net sales break down geographically as follows: Japan (27.1%), China (13.8%), Asia (12.3%), Europe (23.6%), the United States (18.5%) and other (4.7%).
KURARAY CO., LTD 
